These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 27218270)

  • 1. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of APOE ε Genotype on Lipoprotein(a) and the Associated Risk of Myocardial Infarction and Aortic Valve Stenosis.
    Kritharides L; Nordestgaard BG; Tybjærg-Hansen A; Kamstrup PR; Afzal S
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3390-3399. PubMed ID: 28651346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.
    Verbeek R; Boyer M; Boekholdt SM; Hovingh GK; Kastelein JJ; Wareham N; Khaw KT; Arsenault BJ
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):43-48. PubMed ID: 27856457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.
    Benn M; Nordestgaard BG; Grande P; Schnohr P; Tybjaerg-Hansen A
    J Am Coll Cardiol; 2010 Jun; 55(25):2833-42. PubMed ID: 20579540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality.
    Benn M; Tybjærg-Hansen A; Nordestgaard BG
    J Am Coll Cardiol; 2019 Jun; 73(24):3102-3114. PubMed ID: 31221259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
    Mostaza JM; Lahoz C; Salinero-Fort MA; de Dios O; Castillo E; González-Alegre T; García-Iglesias F; Estirado E; Laguna F; Sabín C; López S; Cornejo V; de Burgos C; Sanchez V; Garcés C;
    J Clin Lipidol; 2018; 12(4):1039-1046.e3. PubMed ID: 29773421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low LDL cholesterol,
    Benn M; Nordestgaard BG; Frikke-Schmidt R; Tybjærg-Hansen A
    BMJ; 2017 Apr; 357():j1648. PubMed ID: 28438747
    [No Abstract]   [Full Text] [Related]  

  • 10. Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population.
    Langsted A; Varbo A; Kamstrup PR; Nordestgaard BG
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2690-9. PubMed ID: 25938632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population.
    Guella I; Asselta R; Ardissino D; Merlini PA; Peyvandi F; Kathiresan S; Mannucci PM; Tubaro M; Duga S
    J Lipid Res; 2010 Nov; 51(11):3342-9. PubMed ID: 20699424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.
    Tsai CW; North KE; Tin A; Haack K; Franceschini N; Saroja Voruganti V; Laston S; Zhang Y; Best LG; MacCluer JW; Beaty TH; Navas-Acien A; Kao WH; Howard BV
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E345-9. PubMed ID: 25412415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
    Bonnefond A; Yengo L; Le May C; Fumeron F; Marre M; Balkau B; Charpentier G; Franc S; Froguel P; Cariou B;
    Diabetologia; 2015 Sep; 58(9):2051-5. PubMed ID: 26049403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting proprotein convertase subtilisin kexin type-9 loss of function mutations using plasma PCSK9 concentration.
    Wanneh E; Luna G; Dufour R; Baass A
    J Clin Lipidol; 2017; 11(1):55-60. PubMed ID: 28391911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and In Vitro Inhibition of
    Perrot N; Valerio V; Moschetta D; Boekholdt SM; Dina C; Chen HY; Abner E; Martinsson A; Manikpurage HD; Rigade S; Capoulade R; Mass E; Clavel MA; Le Tourneau T; Messika-Zeitoun D; Wareham NJ; Engert JC; Polvani G; Pibarot P; Esko T; Smith JG; Mathieu P; Thanassoulis G; Schott JJ; Bossé Y; Camera M; Thériault S; Poggio P; Arsenault BJ
    JACC Basic Transl Sci; 2020 Jul; 5(7):649-661. PubMed ID: 32760854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
    Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
    Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.